Search
Research
Early life innate immune signatures of persistent food allergyEarly life innate immune dysfunction may represent a key immunological driver and predictor of persistent food allergy in childhood
Research
Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infantsThe purpose of this article is to highlight emerging evidence for existing allergy prevention guidelines regarding potential benefits of supporting early...
Research
Epigenome-wide association study reveals longitudinally stable DNA methylation differences in CD4+ T cells from children with IgE-mediated food allergyFood allergy is mediated by a combination of genetic and environmental risk factors, potentially mediated by epigenetic mechanisms.
Research
Gene-vitamin D interactions on food sensitization: A prospective birth cohort studyIt has been hypothesized that vitamin D deficiency (VDD) contributes to the development of food sensitization (FS) and then food allergy.
Research
Food AllergyFood allergies have become more common in our community, with up to one in ten young children now affected. Reactions can range from mild hives to life threatening anaphylaxis and breathing difficulties. The most common food allergies are to egg, peanut, tree nuts, cow’s milk, fish, shellfish, sesame, wheat and soy.
Research
Early introduction of food reduces food allergy – Pro and ConWhen an infant is developmentally ready, a variety of nutritious foods should be introduced including the ‘more allergenic’ foods during infancy
Research
Genome-wide association study identifies peanut allergy-specific loci and evidence of epigenetic mediation in US childrenFood allergy (FA) affects 2%-10% of US children and is a growing clinical and public health problem.
Research
EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergyFood allergy can have significant effects on morbidity and quality of life and can be costly in terms of medical visits and treatments.
Research
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPEThe pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years.
News & Events
Back to school anxiety: How to help your child transition into the new school yearAs we count down to the end of the long summer holidays, it’s natural for children to feel anxious about what the new school year will bring.